The Contiform incontinence device - efficacy and patient acceptability.
A consecutive series of 59 women with urodynamic stress incontinence but no prolapse were offered treatment with Contiform (available in small/medium/large sizes). The 24-h pad test was the primary outcome measure. Of the 59 enrolled women, 41 (69%) completed the trial protocol. Median use was 21 days (IQR 10-24.5). Two severity groups were categorized based on pretreatment pad testing (mild <30 g/day n=24 patients, 59%) and moderate/severe >30 g/day, n= 17(41%). Overall, loss was reduced by a median of 72% (5-92), p<0.0001, with the greatest reduction seen in the moderate/severe group of 85% (75-100) p<0.0001. No significant benefit on pad testing was noted in the mild group. Both groups showed significant benefit on the Incontinence Impact Questionnaire. The insertion technique was quickly learnt and the device well tolerated. A medium-sized Contiform was used by 33 (80%) women. No serious adverse events occurred.
Morris
A R
AR
Pelvic Floor Unit, St George Hospital, Pitney Clinical Sciences Building, Level 1, Kogarah, NSW 2117, Sydney, Australia.
Moore
K H
KH
D000328:Adult; D004867:Equipment Design; D005260:Female; D006801:Humans; D008875:Middle Aged; D017060:Patient Satisfaction; D010570:Pessaries; D016896:Treatment Outcome; D014550:Urinary Incontinence, Stress / Q000628:therapy*